Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemiaAmir T. Fathi, Yi‐Bin Chen, Philip C. Amrein et al.|Haematologica|2016Cited by 43
Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance‐conferring FLT3/tyrosine kinase domain/F691 mutationAmir T. Fathi, Mark J. Levis, Traci M. Blonquist et al.|Cancer|2017Cited by 31